Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.
Morán T, et al. Among authors: sanchez s.
Oncotarget. 2018 Jun 5;9(43):27074-27086. doi: 10.18632/oncotarget.25478. eCollection 2018 Jun 5.
Oncotarget. 2018.
PMID: 29930751
Free PMC article.